Measuring Acute Drug Demand in Humans

NCT05829655 EARLY_PHASE1 SUSPENDED

This research is being done to evaluate whether suvorexant may reduce the use of, subjective liking, and demand for various drugs.

Details

Lead sponsor	University of Maryland, Baltimore
Phase	EARLY_PHASE1
Status	SUSPENDED
Enrolment	75
Start date	Tue Aug 08 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sun Oct 31 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Opioid Use Disorder
• Opioid Dependence

Interventions

• Drug A (Blinded Drug)
• Drug B (Blinded Drug)
• Drug C (Blinded Drug)
• Drug D (Blinded Drug)
• Suvorexant (20mg/day)
• Placebo

Countries

United States